Communique from annual general meeting in prostatype genomics AB (publ)
The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the “Company”) was held on 1 June 2023 whereby the shareholders resolved on the following matters.Annual report and results The annual general meeting adopted the income statement and the balance sheet for the financial year 2022 and resolved, in accordance with the board of directors’ proposal, that the result according to the approved income statement should be transferred to a new account. No dividends are to be paid. Discharge from liability The general meeting granted the board of directors